This information is only for medical professionals’ reference. If you are a medical professional, please click "OK" to view the page. If not, click "Cancel".
You are now leaving the Chinese webpage of Gilead Science. You have chosen to visit a third-party website, which is provided by Gilead Science to its visitors. Gilead Science does not have a privacy policy for the third-party website, so we encourage you to re-read the latter’s privacy terms during your visit. Click "Cancel" to go back to the current Chinese webpage of Gilead Science, and click "OK" to visit the third-party website.
Contact
#Header Link Separator#
Sitemap
#Header Link Separator#
中文
About
Senior Management
Research
Responsibility
Business Conduct/Ethics
Medicines
Responsibility
Giving in China
How to Apply
Terms and Conditions
News
Press Releases
Gilead China
More Information
Careers
Exit Player
Loading the player ...
News
Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19
2020/10/09
An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences
2020/10/09
GILEAD’S MAGROLIMAB, AN INVESTIGATIONAL ANTI-CD47 MONOCLONAL ANTIBODY, RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR TREATMENT OF MYELODYSPLASTIC SYNDROME
2020/09/17
Follow us on WebChat